title: [Susceptibility genes, HLA and diabetic retinopathy in the Algerian population].
abstract: BACKGROUND
  Diabetic retinopathy (DR) is the most frequent microvascular complication of type I diabetes (T1D). Some well-controlled type I diabetics may develop DR, while other poorly-controlled diabetics do not develop DR. This might be explained by certain susceptibility genes or protective genes. The purpose of our study is to search for any association between the HLA class I and II markers and DR in the Algerian population.
  
  
  METHODS
  This study was carried out in 52 T1D subjects with and without DR compared to 140 healthy controls. HLA typing was performed using the "microlymphocytotoxicity" technique.
  
  
  RESULTS
  The frequency of HLA-A29 and HLA-DR9 antigens is higher in T1D with DR compared to T1D without DR and to controls with frequencies of HLA-A29 (59.26% vs. 0%, OR=∞, pc=4.6×10(-7)), (59.26% vs. 5.66%, OR=24.24, pc=7.6×10-10) and HLA-DR9 (29.63% vs. 0%, OR=∞, pc=1.310(-3)), (29.63% vs. 4.29%, OR=9.40, pc=7.010(-5)) respectively. However, the frequency of HLA-B49 antigen is significantly lower in T1D with DR than in T1D without DR (3.7% vs. 28%, OR=0.10, pc=8.8×10(-3)) and compared to controls (3.7% vs. 22.64%, OR=0.13, pc=0.011).
  
  
  CONCLUSIONS
  HLA-A29 and HLA-DR9 antigens are probably markers of susceptibility for DR while HLA-B49 antigen is probably associated with a protective effect in the Algerian population.
authors.affiliation: Laboratoire de biologie cellulaire et moléculaire, faculté des sciences biologiques, université des sciences et de la technologie, Houari Boumediene, Bab Ezzouar, Alger, Algérie. raache_ipa@yahoo.fr
authors.forename: R
authors.initials: R
authors.lastname: Raache
authors.forename: R
authors.initials: R
authors.lastname: Hennachi
authors.forename: H
authors.initials: H
authors.lastname: Amroune
authors.forename: A
authors.initials: A
authors.lastname: Heniche
authors.forename: K
authors.initials: K
authors.lastname: Belanteur
authors.forename: A
authors.initials: A
authors.lastname: Benyahia
authors.forename: K S
authors.initials: KS
authors.lastname: Ouandjeli
authors.forename: A
authors.initials: A
authors.lastname: Barar
authors.forename: D
authors.initials: D
authors.lastname: Houhou
authors.forename: S
authors.initials: S
authors.lastname: Mimouni
authors.forename: T
authors.initials: T
authors.lastname: Gervais
authors.forename: D
authors.initials: D
authors.lastname: Latinne
authors.forename: A
authors.initials: A
authors.lastname: Boudiba
authors.forename: N
authors.initials: N
authors.lastname: Attal
authors.forename: M C
authors.initials: MC
authors.lastname: Abbadi
mesh_terms: D000328:Adult; D000462:Algeria / Q000453:epidemiology; D003601:Cytotoxicity Tests, Immunologic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications; D003930:Diabetic Retinopathy / Q000097:blood / Q000208:ethnology / Q000235:genetics*; D005006:Ethnicity / Q000235:genetics; D005260:Female; D005805:Genes, MHC Class I; D005802:Genes, MHC Class II; D020022:Genetic Predisposition to Disease; D006680:HLA Antigens / Q000235:genetics*; D015234:HLA-A Antigens / Q000235:genetics; D015235:HLA-B Antigens / Q000235:genetics; D059810:HLA-DR Serological Subtypes / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D055815:Young Adult
chemical_list: D006680:HLA Antigens; D015234:HLA-A Antigens; C035524:HLA-A29 antigen; D015235:HLA-B Antigens; C483912:HLA-B*49 antigen; D059810:HLA-DR Serological Subtypes; C038988:HLA-DR9 antigen